Background {#Sec1}
==========

The *BRCA1-associated protein 1 (BAP1)* gene is located on chromosome 3p21 and encodes a nuclear localized, ubiquitin carboxy-terminal hydrolase tumor suppressor protein \[[@CR1], [@CR2]\]. BAP1 has been shown to bind to the BRCA1 protein enhancing BRCA1-mediated tumor suppression, and is involved in various biological processes including DNA damage response, regulation of the cell cycle and cell growth \[[@CR2], [@CR3]\]. Germline *BAP1* mutations have been associated with hereditary predisposition to multiple different cancers that include uveal and cutaneous melanoma, malignant mesothelioma on exposure to asbestos, renal cell carcinoma and other cancer types, such as lung adenocarcinoma and meningioma, that are collectively referred to as *BAP1* Tumor Predisposition Syndrome (*BAP1*-TPDS, OMIM \#614327) \[[@CR4], [@CR5]\]. In vivo studies in melanocytic cells, have shown that *BAP1* is involved in the maintenance of a melanocytic phenotype; the depletion of BAP1 protein levels result in dedifferentiation of cells and the acquisition of a more primitive, stem cell like phenotype \[[@CR6]\]. It is well established that the *BAP1* region of chromosome 3p is commonly deleted in several cancers including melanomas, breast and lung cancers, among others \[[@CR1], [@CR7]\].

Uveal melanoma (UM) is a rare malignant tumor of the eye with a frequency of 5.1 per million in the United States \[[@CR8]\], and is the cancer most commonly associated with the *BAP1*-TPDS \[[@CR9]\]. The prognosis for UM is poor in approximately 50% of cases primarily due to metastasis to the liver within a short time \[[@CR10], [@CR11]\]. Factors such as large tumor size, location and chromosome 3 monosomy \[[@CR12]--[@CR18]\], as well as a specific 12-gene expression pattern \[[@CR19]--[@CR21]\] have all been associated with an increased risk of metastasis. In addition, the presence of inactivating somatic \[[@CR22]--[@CR29]\] or germline \[[@CR30]\] *BAP1* mutations often in conjunction with chromosome 3 monosomy, loss of *BAP1* expression, or lack of immunohistochemical staining, have all been associated with metastasizing UM.

Germline *BAP1* mutations have been identified in approximately 2-5% of UM unselected for the presence of any high risk of hereditary cancers \[[@CR30]--[@CR33]\]. These studies reported that metastasis occurred more frequently in UM carrying germline mutations in the blood compared to *BAP1* mutation-negative controls, but the differences were significant only in one study \[[@CR30]\], possibly due to the small number of tumors with germline mutations. In studies where DNA from both tumor tissue and blood was sequenced to rule out the presence of germline mutations, the frequency of somatic *BAP1* mutations was considerably higher than that observed in tumors with germline mutations, approaching 50% \[[@CR23], [@CR27], [@CR34]\]. In other studies where somatic mutations were detected by BAP1 expression assays and/or negative immunohistochemical staining methods, as well as sequencing, the lack of BAP1 expression was also significantly associated with the risk of metastasis \[[@CR22]--[@CR29]\]. While these studies show a strong association between somatic *BAP1* mutations and metastasis, the effect of germline changes remains unclear.

Most studies of *BAP1* mutation status in UM have been carried out using enucleated UM which may not be representative of how UM are currently treated, especially smaller tumors that are treated with globe sparing procedures. In this study of *BAP1* mutations in UM, the presence of germline or somatic mutations was determined using sequence analysis of DNA extracted from biopsies of both enucleated globes and fine needle aspirations (FNA) and from matched blood samples. Demographic and clinical characteristics of the tumors and the frequency of metastasis were compared among tumors with germline or somatic *BAP1* mutations and mutation-negative UM.

Methods {#Sec2}
=======

UM cases {#Sec3}
--------

A total of 142 UM cases managed by the Ocular Oncology Service at Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA between 1998 and 2016 were evaluated in this study of somatic and germline *BAP1* mutations. Twenty-three tumor samples were obtained by solid open biopsy of enucleated UM and 119 by fine needle aspirate (FNA) biopsies. Matched peripheral blood samples were obtained from all 142 individuals. Data on demographic and clinical characteristics, metastatic status, location of metastasis and relevant follow-up times were obtained by retrospective chart reviews. Written informed consent was obtained for all individuals at the time of chromosome testing of the tumor DNA. This research was approved by the Institutional Review Board of the University of Pennsylvania, and is in accordance with the Declaration of Helsinki.

The 142 UM were initially collected from two cohorts. Cohort 1 cases (N=90) were chosen from a series of tumors diagnosed between 1998 and 2013 based on availability of matched tumor and blood samples. Cohort 2 consisted of 52 cases diagnosed between 2008 and 2016 for which *BAP1* testing was requested, typically due to a personal and/or family history of cancer. The decision to combine the two sets of tumors into a single cohort for analysis was based on the finding that cohort membership was not a significant variable in either univariate (*P*=0.53) or multivariate (*P*=0.65) Cox regression analysis (Table [1](#Tab1){ref-type="table"}). In addition, there was no significant difference between the two cohorts in the relative number of tumors carrying germline or somatic *BAP1* mutations and mutation*-*negative tumors (*P*= 0.76), or in the number of cases with personal or family history of *BAP1*-TPDS cancers (P=0.35, see below and Additional file [1](#MOESM1){ref-type="media"}: Table S1). There was a significant difference in the time to metastasis (P=0.01) and in the number of metastases (P=0.003) between the two cohorts, possibly due to a longer follow-up time for the cohort 1 tumors (median=85 months, range 6-191) compared to 24 months (range 4-77 months, *P*\<0.001, Additional file [1](#MOESM1){ref-type="media"}: Table S1) for cohort 2. However, taking both metastasis and follow-up time into account in a Kaplan-Meier analysis, there was no significant association between cohort membership and metastasis (*P*=0.52, Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Table 1Demographic and tumor characteristics for 142 UM and assessment of their association with metastasis evaluated by Cox univariate regression for each of the nine variables alone, and multivariate regression that included all variables described in the tableVariablesAll tumors *N*=142 (frequency)Univariate regressionMultivariate regression*P*-valueHazard ratio95% confidence intervals*P*-valueHazard ratio95% confidence intervalsCohort 190 (0.63)referencereference 252 (0.37)0.530.820.44-1.530.651.180.57-2.48Source of biopsied sample^a^ FNA, N=119 (0.84)referencereference  BAP1 mutation negative73 (0.61)  BAP1 mutation positive46 (0.39) Enucleated tumor, N= 23 (0.16)**0.01**2.121.19-3.760.082.040.92-4.52  BAP1 mutation negative15 (0.65)  BAP1 mutation positive8 (0.35)Age (years)**0.04**1.021.00-1.04**0.03**1.021.00-1.05 Median56.7 Mean±SD55.4±14.7 Range14-88Sex Male77 (0.54)referencereference Female65 (0.46)0.240.730.43-1.240.730.900.50-1.63Chromosome 3 Disomy63 (0.44)referencereference Monosomy, partial monosomy (N=2), mosaic (N=5)79 (0.56)**\<0.001**4.642.46-8.78**0.008**2.991.33-6.72Tumor diameter (mm)**\<0.001**1.251.17-1.35**\<0.001**1.201.10-1.31 Median12.0 Mean±SD12.5±4.1 Range5.0-22.0Tumor thickness (mm)**\<0.001**1.221.13-1.310.610.970.87-1.09 Median5.7 Mean±SD6.2±3.3, Range1.0-16.5Ciliary body involvement Absent110 (0.78)**\<0.001**referencereference Present32 (0.22)3.051.79-5.200.151.540.85-2.80*BAP1* Negative88 (0.62)referencereference Somatic43 (0.30)**\<0.001**4.812.79-8.28**0.02**2.201.13-4.30 Germline11 (0.08)0.331.700.59-4.910.810.870.28-2.72^a^There was no significant difference in the number of *BAP1* mutation negative tumors and those carrying germline or somatic mutations UM biopsies from FNA samples compared to enucleated tumors (*P*=0.79, Fisher Exact test)Figures is bold indicate significant *P*-values \<0.05

A personal or family history of *BAP1*-TPDS syndrome, defined following the guidelines found in OMIM \#614327 \[[@CR4]\] and Pilarski et al \[[@CR5]\], was available for a subset of the UM cases. Individuals having at least two *BAP1*-TPDS tumors (UM, cutaneous melanoma, malignant mesothelioma, or renal cell carcinoma) themselves, or one in the UM case plus at least one in a first or second degree relative were considered as indicative of *BAP1*-TPDS syndrome. Cases with non-specific cancer diagnoses were not included as *BAP1*-TPDS syndromic tumors,

*BAP1* mutation screening and chromosome 3 copy number analysis {#Sec4}
---------------------------------------------------------------

Genomic DNA was extracted from peripheral blood lymphocytes using the Gentra Puregene Blood Kit (Cat No.158489, Qiagen) following the manufacturer's protocol, and from tumor samples as described previously \[[@CR15], [@CR35]\]. Sanger sequencing of DNA from matched peripheral blood lymphocytes was used to determine the presence of a germline mutation as noted by Abdel-Rahman et al \[[@CR36]\]. DNA from enucleated tumor or FNA biopsies was sequenced to identify *BAP1* mutations using either Sanger or next generation sequencing of all coding exons and adjacent intronic regions \[[@CR37], [@CR38]\]. Sequence alignment and variant calling was performed as described previously \[[@CR37]\]. The 2015 ACMG guidelines were followed in determining the degree pathogenicity of all sequence variants \[[@CR39]\].

Chromosome 3 copy number was determined by microsatellite analysis (*N*=51) or whole genome SNP array (Affymetrix Human 100K, SNP-5.0 or SNP-6.0 and Cytoscan HD genotyping arrays, Affymetrix, Santa Clara CA) \[[@CR15], [@CR35]\]. Tumors were categorized as either disomy-3 (*N*=63) or monosomy (*N*=79) that included 72 tumors with complete monosomy-3, two with partial monosomy and five with a mosaic monosomy 3 indicating tumor heterogeneity of cells with chromosome-3 disomy and monosomy.

Statistical analyses {#Sec5}
--------------------

Continuous variables (age, tumor diameter and thickness) were compared using a Mann-Whitney U-test, and discrete variables (source of tumor sample, cohort 1 or 2, metastasis status, sex, tumor location and chromosome 3 copy number) using Fisher Exact or chi-square tests ([vassarstats.net](http://vassarstats.net)). Cox univariate and multivariate proportional hazard regression was used to determine the association of clinical and tumor characteristics with metastasis. The Kaplan-Meier method was used to generate metastasis-free survival curves that were compared using a log-rank test. SPSS 24 (IBM, New York, NY) was used for survival analysis procedures. All tests were two-tailed and P-values less than 0.05 were considered statistically significant.

Results {#Sec6}
=======

UM individuals and tumor characteristics {#Sec7}
----------------------------------------

Of the 142 UM characterized in this study, 54 (38%) carried a *BAP1* gene mutation. Eleven (8%) of the mutations were germline and 43 (30%) were somatic. The remaining 88 (62%) were *BAP1* mutation-negative. The eleven germline mutations were all retained in the matched UM samples. Thus, there were no cases where a germline mutation was lost in tumors, with or without monosomy-3.

Demographic and tumor characteristics for the 142 UM cases are shown in Table [1](#Tab1){ref-type="table"}. The median age of all individuals was 56.7 years (range=14-88), and 77 (54%) were males. Overall, 63 (44%) of the tumors carried two copies of chromosome 3 (disomy), and 79 (56%) carried one copy of chromosome 3 (monosomy), partial monosomy or mosaic. The median tumor diameter and thickness was 12 mm (range=5.0-22.0) and 5.7 mm (range 1.0-16.5), respectively. The majority of the tumors had no ciliary body involvement (*N*=110, 78%). Most tumors were located only in the choroid (*N*=109, 77%), 26 (18%) were in the choroid plus ciliary body, three (2%) in the ciliary body, one (1%) in the iris, two (2%) in the iris plus ciliary body, and one (1%) in the iris plus ciliary body and choroid. Fifty-nine tumors (42%) metastasized within a median time of 19 months (range=0-107) while 83 (58%) did not metastasize during the observed follow-up period (median=56 months, range=4-191 months, Table [2](#Tab2){ref-type="table"}). Thirty-six of 54 tumors with *BAP1* mutations metastasized (67%) compared to only 23 of 88 (26%) mutation-negative tumors (*P*\<0.001) within 2-107 months.Table 2Description of demographic and tumor variables with pairwise comparisons for 11 tumors with germline BAP1 mutations, 43 with *BAP1* somatic mutations and 88 with no *BAP1* mutationsVariables*BAP1* germline*BAP1* somatic*BAP1* negativePairwise comparisons (*P*-value)*N*=11 (0.08) (frequency)*N*=43 (0.30) (frequency)*N*=88 (0.62) (frequency)Germline/SomaticGermline/NegativeSomatic/NegativeMetastases Yes N=59 (0.42)4 (0.36)32 (0.74)23 (0.26)**0.03** ^a^0.72^a^**\<0.001** ^a^ No N=83 (0.58)7 (0.64)11 (0.26)65 (0.74)Time to metastasis (months) (*N*=59)N=4 (0.07)N=32 (0.54)N=23 (0.38)0.07^b^0.50^b^**0.04** ^c^ Median (19.0 months)37.516.026.0 Mean±SD (26.4±20.9)35.0±15.823±22.529.7±19.2 Range (0-107)16-492-45,90,107^d^0-84Follow-up time (months) in tumors with no metastasis (*N*=83)N=7 (0.08)N=11 (0.13)N=65 (0.78)0.59^c^0.25^c^0.33^c^ Median (56.0 months)2454.058.0 Mean±SD (59.8±39.0)43.7±39.349.9±30.063.2±40.1 Range (4-191)4-1098-905-191Cohort 16 (0.54)27 (0.63)57 (0.65)0.73^a^0.74^a^0.85^a^ 25 (0.46)16 (0.37)31 (0.35)Source of biopsied sample FNA10 (0.91)36 (0.84)73 (0.83)0.68^a^0.69^a^1.00^a^ Enucleated tumor1 (0.09)7 (0.16)15 (0.17)*BAP1*-TPDS personal or family history (*N*=79 reports)^e^ Yes, syndromic tumors present (*N*=29, 0.37)8 (1.00)10 (0.44)11 (0.23)**0.009** ^a^**\<0.001** ^a^0.10 No syndromic tumors (N=50, 0.63)013 (0.56)37 (0.77)Age (years) Median59.061.852.20.07^c^0.86^c^**0.002** ^c^ Mean±SD51.9±13.661.2±12.853.1±15.0, Range22-6728-8814-84Sex Male7 (0.64)25 (0.58)45 (0.51)1.00^a^0.53^a^0.46^a^ Female4 (0.36)18 (0.42)43 (0.49)Chromosome 3 Disomy1 (0.09)3 (0.07)59 (0.67)1.0^a^**\<0.001** ^a^**\<0.001** ^a^ Monosomy, partial monosomy (*N*=2), mosaic (*N*=5)10 (0.91)40 (0.93)26 (0.33)Tumor diameter (mm) Median14.014.011.50.70^c^0.23^c^**0.003** ^c^ Mean±SD13.4±4.413.9±3.911.7±4.0, Range8.0-20.06.0-21.55.0-22.0Tumor thickness (mm) Median6.67.05.00.41^c^0.51^c^**0.002** ^c^ Mean±SD6.5±3.67.5±3.55.6±2.9, Range1.5-12.32.0-16.51.0-13.1Ciliary body involvement Absent8 (0.73)28 (0.65)74 (0.84)0.73^a^0.40^a^**0.02** ^a^ Present3 (0.27)15 (0.35)14 (0.14)^a^Association test performed using two-tailed Fisher Exact or Chi-square tests^b^Reported P-values are calculated from a normal approximation of the Mann Whitney test statistic^c^Tests of means of quantitative variables performed using Mann-Whitney U tests^d^The time for metastasis for 30 of the tumors with somatic mutations was 2-45 months. The time to metastasis for the remaining two tumors was 90 and 107 months^e^*BAP1*-TPDS, *BAP1*-tumor predisposition syndrome as defined in OMIM \#614327 \[[@CR4]\] and Pilarski et al \[[@CR5]\]Figures is bold indicate significant P-values \<0.05

*BAP1* status was determined for 119 (84%) FNA biopsies and 23 enucleated tumors (Table [1](#Tab1){ref-type="table"}). There was a significant difference in the number of metastases depending on the source of the biopsied sample: 43 of 119 (36%) tumors biopsied from FNA metastasized compared to 16 of 23 from enucleated globes (70%, *P*=0.006). The source of the biopsied sample was also significantly associated with metastasis in a Cox univariate (*P*=0.01), but not in a multivariate analysis (0.08, Table [1](#Tab1){ref-type="table"}). This is not surprising, however, given that some of the classic prognostic factors for UM metastasis, larger tumor diameter and thickness and tumor location which warrant enucleation, were significantly different between tumors sampled from FNAs or enucleated tumor samples (*P*=0.002, \>0.001 and 0.02, respectively (data not shown). Importantly, there was no difference in the number of tumors carrying a germline or somatic mutation or mutation-negative tumors in enucleated tumors compared to FNA samples (*P*=0.79, Table [1](#Tab1){ref-type="table"} footnote^a^).

In a Cox univariate analysis, the presence of a somatic, but not a germline *BAP1* mutation (hazard ratio (HR) =4.81, *P*\<0.0001; HR=1.7, *P*=0.33, respectively, Table [1](#Tab1){ref-type="table"}) was significantly associated with metastasis. Other tumor variables that were significant in the univariate regression analysis included tumor source (FNA or enucleated tumor, HR= 2.12; *P*=0.01), age HR=1.02, *P*=0.04), chromosome 3 monosomy, larger tumor diameter and thickness, and ciliary body involvement (HR=4.64, 1.25 and 1.22, respectively; all *P*≤0.001). Considering all variables in a multivariate analysis, the presence of a somatic *BAP1* mutation (HR=2.20, P=0.02), age (HR=1.02, *P*=0.03) tumor diameter (HR=1.20, *P*\<0.001), and chromosome 3 monosomy (HR=2.99, *P*=0.008) remained significant, while the presence of a germline mutation was not significant (HR=0.87, *P*=0.81).

*BAP1* Gene Mutations {#Sec8}
---------------------

Fifty-two unique *BAP1* mutations were identified in 54 tumors: 43 tumors (30%) carried somatic mutations, while 11 tumors (8%) carried germline mutations (Table [3](#Tab3){ref-type="table"}). All mutations were defined as pathogenic or likely pathogenic. These included seven (13%) missense and 15 (28%) splice-site mutations, three (6%) in-frame deletions and 29 mutations causing premature truncation, including one large deletion encompassing exons 15-17 and the intervening introns. There was no significant difference in the frequencies of these categories of mutations found in UM with germline compared to somatic mutations (*P*=1.0), nor in tumors that metastasized compared to those that did not (*P*=0.53). Thirty-six (67%) of the mutations were in the catalytic UCH domain. One splice-site mutation, c.438-1A\>G was present as a germline mutation in one tumor (UM-23) and as a somatic mutation in two tumors (UM-11 and UM-27). Thirty-three of these mutations were previously described in UM by Ewens et al \[[@CR37]\] and 13 have been identified in UM by others (as noted in Table [3](#Tab3){ref-type="table"}). Although the number of germline mutations was small (*N*=11), the locations of these were spread throughout the gene, similar to the distribution of somatic mutations (Table [3](#Tab3){ref-type="table"}). Therefore, no new information was inferred from the location, or the associated functional domains, that would make the germline mutations have unique characteristic compared to somatic mutations.Table 3Fifty-two unique germline and somatic *BAP1* mutations identified in 54 UMIDBAP1 mutationMetastaseschr 3DNA changeProtein changePredictred effectPredicted pathogenic effect^a^Previously reported mutations in UMUM_44germlineyesmonosomyexon 1c.3G\>Ap.Met1Ilemisense: start site lostLP\[[@CR36]\]UM_76somaticyesmonosomyintron 1c.38-1G\>Cp.?splicingP\[[@CR36]\]UM_9somaticyesmonosomyexon 2c.40_52del13p.Leu14SerfsTer54truncatingP\[[@CR36]\]UM_1136germlinenomonosomyexon 2c.58_59insTGp.Glu20ValfsTer53truncatingPUM_113somaticyesmonosomyintron 2c.67+1G\>Ap.?splicingP\[[@CR27], [@CR36]\]UM_1123somaticyesmonosomyintron 2c.67+2dupTp.?splicingPUM_1080somaticnomonosomyintron 2/exon 3c.68-12_75del20p.?splicingPUM_802somaticyesmonosomyintron 2/exon 3c.68-16_69del18p.?splicingP\[[@CR36]\]UM_584germlinenomonosomyexon 3c.79delGp.Val27CysfsTer45truncatingPUM_17somaticyesmonosomyexon 3c.82C\>Tp.Gln28TertruncatingP\[[@CR36]\]UM_1207somaticnomonosomyexon 3c.91_93delGAGp.Glu31delin-frame deletionLPUM_1133germlinenodisomy^b^intron 3c.122+1G\>Cp.?splicingPUM_109germlineyesmonosomyintron 3c.122+1G\>Tp.?splicingP\[[@CR36]\]UM_75somaticnomonosomyexon 4c.125_145del21p.Pro42_Phe48delin-frame deletionLP\[[@CR36]\]UM_88somaticyesmonosomyexon 4c.145delCp.Leu49CysfsTer23truncatingP\[[@CR36]\]UM_877somaticyesmonosomyexon 4c.165_180del16p.Arg57SerfsTer10truncatingPUM_13somaticyesdisomy^b^exon 4c.178C\>Tp.Arg60TertruncatingP\[[@CR36], [@CR45]\]UM_62somaticyesmonosomyexon 4c.202_227del26p.Asp68CysfsTer3truncatingP\[[@CR36]\]UM_780somaticyesmonosomyexon 4/intron 4c.234del96p.?splicingPUM_119somaticyesmonosomyexon 4c.253C\>Tp.Gln85TertruncatingP\[[@CR36]\]UM_106somaticyesmonosomyexon 4c.254A\>Cp.Gln85PromissenseP\[[@CR36]\]UM_1126somaticnomonosomyexon 5c.295_312del18p.Val99_Ser104delin-frame deletionLPUM_1046somaticnomonosomyexon5/intron5c.370_375+12del18p.?splicingPUM_1208somaticyesmonosomyintron 5/exon 6c.376-20_383del28p.?splicingPUM_56somaticyesmonosomyexon 6c.422A\>Gp.His141ArgmissenseLP\[[@CR36], [@CR46]\]UM_23germlineyesmonosomyintron 6c.438-2A\>Gp.?splicingP\[[@CR36]\]UM_11somaticnodisomy^b^intron 6c.438-2A\>Gp.?splicingPUM_27somaticyesmonosomyintron 6c.438-2A\>Gp.?splicingPUM_58germlinenomonosomyexon 7c.458_459delCTp.Pro153ArgfsTer7truncatingP\[[@CR9], [@CR36]\]UM_114somaticyesmonosomyexon 7c.497_509del13p.Glu166ValfsTer17truncatingP\[[@CR36]\]UM_51somaticnomonosomyexon 7c.506A\>Cp.His169PromissenseP\[[@CR36]\]UM_1118somaticnomonosomyexon 7c.524C\>Gp.Pro175ArgmissenseLP\[[@CR27]\]UM_1086somaticyesmonosomyintron 7/exon 8c.581-2_591del13p.?splicingPUM_60somaticyesmonosomyexon 8c.588G\>Ap.Trp196TertruncatingP\[[@CR23], [@CR47]\]UM_1334germlinenomosaicexon 8c.619delCp.Arg207GlyfsTer24truncatingPUM_105somaticyesmonosomyintron 8c.659+1G\>Ap.?splicingP\[[@CR27], [@CR36]\]UM_35somaticyesmonosomyexon 9c.723T\>Ap.Tyr241TertruncatingP\[[@CR36], [@CR48]:c.723T\>C\]UM_107somaticyesmonosomyexon 9c.781C\>Tp.Gln261TertruncatingP\[[@CR36], [@CR49]\] rs772448753^c^UM_46somaticyesmonosomyexon 10c.904_905insTp.Pro302LeufsTer5truncatingP\[[@CR36]\]UM_1029somaticyesmonosomyexon 12c.1134_1143del10_insAAp.Ala379ArgfsTer16truncatingPUM_115somaticyesmonosomyexon 12c.1153C\>Tp.Arg385TertruncatingP\[[@CR32], [@CR36], [@CR44], [@CR50]\]UM_55somaticnomonosomyexon 12c.1175_1182delAGCAGTACp.Gln392LeufsTer3truncatingP\[[@CR36]\]UM_863somaticnomonosomyexon 12c.1192G\>Tp.Glu398TertruncatingPUM_950germlineyesmosaicexon 12c.1203dupTp.Glu402TertruncatingPUM_69somaticyesmonosomyexon 12c.1217_1220delAGGAp.Glu406ValfsTer23truncatingP\[[@CR36]\]UM_1333germlinenomosaicexon 13c.1695dupTp.Glu566TertruncatingPUM_48somaticnomonosomyexon 13c.1729G\>Cp.Glu577GlnmissenseP\[[@CR36]\]UM_61somaticyesmonosomyexon 14c.1881C\>Gp.Tyr627TertruncatingP\[[@CR36]\]UM_74germlinenomonosomyexon 14c.1882_1885delTCACp.Ser628ProfsTer8truncatingP\[[@CR29], [@CR36], [@CR51]\]UM_708somaticnodisomy^b^intron 14-3\'UTRc.1890+38_2573delp.Glu631Tertruncating (3 exon deletion)PUM_1113somaticyesmonosomyexon 15c.1926_1951del 26p.Ile643GlyfsTer12truncatingPUM_104somaticyesmonosomyexon 15c.1932_1948deldel17p.Asn645GlnfsTer13truncatingP\[[@CR36]\]UM_804somaticyesmonosomyexon 16c.1986_1989delTGATp.Ile662MetfsTer29truncatingP\[[@CR36]\]UM_108somaticyesmonosomyexon 16c.2015A\>Gp.Asp672GlymissenseLP\[[@CR23], [@CR36]\]^a^Predicted pathogenic effect based on ACMG guidelines \[[@CR39]\] P, pathogenic; LP, likely pathogenic^b^indicates UM with chromosome 3 disomy and carrying a germline or somatic BAP1 mutation\*\*Population frequency rs772448753: 8.2E-06

Characterizations of UM with and without *BAP1* mutations {#Sec9}
---------------------------------------------------------

Clinical and tumor characteristics of UM carrying *BAP1* germline or somatic mutations and mutation-negative tumors, as well as pairwise comparisons of the three groups are presented in Table [2](#Tab2){ref-type="table"}. There was no significant difference in the cohort, source of biopsy sample, or sex of the individuals among the three categories of mutations. The age at diagnosis of individuals with somatic mutations was significantly older (61.8 years, range=28-88) than individuals with mutation-negative tumors (median=52.2 years, range=14-84 years, *P*=0.002) and approached significance compared to individuals with a tumor carrying a germline mutation (median=59.0 years, range=22-67, *P*=0.07).

There was a significant difference in the comparison of chromosome 3 monosomy in mutation-negative tumors compared to tumors with either germline or somatic mutations. Only 26 (33%) mutation-negative tumors carried monosomy 3, while ten (91%) tumors with germline mutations and 40 (93%) with somatic mutations were chromosome 3 monosomy (*P*\<0.001 in both cases). A comparison of chromosome 3 copy number between tumors with germline vs. somatic mutations (91% vs. 93%) was not significant (*P*=1.0, Table [2](#Tab2){ref-type="table"}). There were four tumors with *BAP1* mutations and chromosome 3 disomy (marked with superscript b in Table [3](#Tab3){ref-type="table"}). These would suggest that chromosome 3 loss was not a necessary consequence of *BAP1* loss. The one germline mutation was a splice-site mutation, intron 3, c.122+1G\>C. The three somatic mutations included one splice-site mutation (intron 6, c.438-2A\>G) and two truncating mutations: exon 4, c.178C\>T (p.Arg60X) and a large deletion of exons 15-17 and the intervening introns. The tumor carrying the exon 4, c.178C\>T (p.Arg60X) truncating mutation metastasized at 11 months, but the other three tumors had not metastasized within 24 months (c.122+1G\>C) or within at least 65 months (c.438-2A\>G and the large three exon deletion).

Tumors with *BAP1* somatic mutations had a significantly larger median diameter (14.0 mm, range=6.0-21.5) and thickness (7.0 mm, range=2.0-16.5) compared to mutation negative tumors (median diameter=11.5 mm, range=5.0-22.0; thickness=5.0 mm, range=0.0-13.1, *P*=0.003 and P=0.002 respectively, Table [2](#Tab2){ref-type="table"}). However, there was no significant difference in the tumor diameter or thickness between *BAP1* germline tumors and tumors with either somatic mutations (*P*=0.70 and *P*=0.41, respectively), or *BAP1*-negative tumors (P=0.23 and *P*=0.51, respectively). Table [2](#Tab2){ref-type="table"} shows that there was also a significant difference in ciliary body involvement of tumors carrying a somatic mutation, where the tumor was more likely to have ciliary body involvement (33%) compared to *BAP1*-negative tumors (14%, P=0.04), but not compared with those with a germline mutation (27%, *P*=1.0).

Tumors carrying *BAP1* somatic mutations metastasized significantly more often (32 of 43, 74%) compared to those with either *BAP1* germline mutations (4 of 11, 36%, *P*=0.03) or to *BAP1* mutation-negative tumors (23 of 88, 26%, *P*\<0.001, Table [2](#Tab2){ref-type="table"}). However, there was no significant difference in the frequency of metastasis between tumors with germline mutations and *BAP1*-negative tumors (*P*=0.72). This finding was corroborated by the multivariate regression analyses shown in Table [1](#Tab1){ref-type="table"} indicating that somatic, but not germline *BAP1* mutations, were significantly associated with metastasis (*P*=0.03 and 0.70, respectively). Kaplan-Meier analysis (Figure [1](#Fig1){ref-type="fig"}) also showed that tumors with a *BAP1* somatic mutation had a significantly poorer metastatic outcome compared to those with germline mutations (P=0.03) or mutation-negative tumors (*P*\<0.001), but the difference between tumors with germline mutations and *BAP1* mutation-negative tumors was not significant (P=0.23). The time to metastasis was also significantly shorter in the tumors with somatic mutations (median=16.0 months, range=2-107) compared to *BAP1-negative* tumors (median=26 months, range=0-84 months, *P*=0.04, Table [2](#Tab2){ref-type="table"}).Fig. 1Kaplan-Meier curves showing metastasis-free survival following diagnosis for 142 UM stratified by *BAP1* mutation status

A positive personal and/or family history of *BAP1*-TPDS tumors was reported for 29 (37%) of the 79 cases that provided information of other cancers in themselves or their families (Table [2](#Tab2){ref-type="table"}). There were eight cases that carried a germline mutation with information on personal or familial cancers; all had a positive history of *BAP1*-TPDS. Comparisons of *BAP1*-TPDS tumors in UM cases with a germline (8, 100%) vs. somatic mutation (10, 44%) or germline vs. mutation-negative (11, 23%) were significant (*P*=0.009 and *P*\<0.001, respectively), while a comparison of those with somatic mutations was not significantly different from those with mutation-negative tumors (*P*=0.10)

Discussion {#Sec10}
==========

Inactivating somatic mutations in the *BAP1* gene in UM were first identified and associated with metastatic disease in 2010 \[[@CR23]\]. Subsequent to this original publication, there have been numerous studies characterizing *BAP1* somatic \[[@CR22], [@CR24]--[@CR29], [@CR40]--[@CR43]\] and germline \[[@CR9], [@CR30], [@CR32], [@CR33]\] mutations in UM. However, to our knowledge, this is the first report directly comparing risk of metastasis in tumors carrying germline or somatic *BAP1* mutations and mutation-negative tumors. In this study, the presence of somatic mutations was strictly defined as those found in tumors, and not in matched blood samples. A second important difference in this study is that, compared to most other reports where UM tumors analyzed for *BAP1* mutations were comprised primarily of samples biopsied from larger, enucleated tumors, 84% of the samples analyzed in this study were from FNA biopsies. We found no significant difference in the frequency of somatic and germline mutations in biopsies from FNAs compared to enucleated tumors. Since the majority of UM are currently being treated by globe sparing procedures, it was important to determine whether the consequences of carrying a *BAP1* mutation identified in larger enucleated tumors could be applied to smaller UM biopsied by FNA sampling.

It is well established that tumor characteristics such as tumor diameter, ciliary body involvement and chromosome 3 monosomy are all associated with poor prognosis as measured by the development of metastases within 48 months after the primary is treated \[[@CR12]--[@CR18]\]. It has also been shown that that these same variables are significantly associated with *BAP1* mutation status in tumors with somatic or germline mutations \[[@CR24], [@CR25], [@CR28], [@CR30]\]. In this study, multivariate regression analysis showed that in addition to these classic tumor variables, the presence of somatic, but not germline, *BAP1* mutations was significantly associated with metastasis (HR=2.20, *P*=0.02; HR=0.87, P=0.81, respectively). Kaplan-Meier analysis further showed that tumors with somatic mutations were associated with the poorest metastatic outcome, while there was no significant difference between tumors carrying a germline mutation and mutation-negative tumors. Furthermore, the time to metastasis was seven months shorter for individuals whose tumors carried somatic mutations compared to mutation-negative tumors (*P*=0.04) suggesting a more aggressive phenotype. Thus, in a previous publication \[[@CR37]\] we showed that tumors with any mutation in the *BAP1* gene, in combination with chromosome 3-monosomy, have the highest risk of metastasis (HR=11.5). In this manuscript we show that monosomy 3 plus a somatic mutation in the *BAP1* gene, as opposed to a germline mutation, have a significantly higher risk of metastasis (*P*=0.01, H.R.=2.81) and a shorter time to metastasis compared to the ones with a germline mutation.

Given that somatic *BAP1* mutations appear to have a highly significant association with poor metastatic prognosis, it is surprising that the age of diagnosis of the individuals whose tumors carried somatic mutations was significantly older (median=61.8 years) compared to those with mutation-negative tumors (median=52.2 years, *P*=0.002). Previous studies have also reported that tumors with somatic mutations were diagnosed at least 8 years later than mutation-negative controls \[[@CR24], [@CR27], [@CR29]\], but the significance of this observation is not clear.

Among the 54 tumors with *BAP1* mutations, there were four with chromosome 3 disomy. It cannot be ruled out that although these tumors appeared to be disomy-3, small deletions not detectable on the SNP arrays leading to partial monosomy or heterogeneity of the tumor sample could be responsible for this finding. Alternatively, in some cases it is possible the during tumor evolution, *BAP1* mutation on one copy of chromosome 3 could precede the loss of the other copy of chromosome 3. While several studies have found total concordance between the presence *BAP1* mutations and monosomy 3 \[[@CR23], [@CR27], [@CR40]\], others using sequencing, gene expression, and/or immunostaining methods have identified *BAP1* mutations in a small number of tumors with disomy 3 \[[@CR24], [@CR25], [@CR28], [@CR44]\].

One interesting observation in this study was the presence of *BAP1*-TPDS history in 44% of somatic cases and 23% of mutation negative tumors. The data on *BAP1*-TPDS was based on self-reported personal and family history of cancer. We classified individuals as having *BAP1*-TPDS if they carried at least two relevant tumors in their personal or family history. Since it is self-reported, the information can be imprecise, and there is a possibility for over/under representation of the *BAP1-*TPDS cases as well.

While the presence of germline *BAP1* mutations in cancers associated with *BAP1*-TPSD is well documented, the role of somatic mutations in this syndrome is not well studied. It is possible that the presence of TPDS in our cohort of UM cases that have a somatic *BAP1* mutation or are mutation-negative could be interpreted as evidence for the existence of a second type of the syndrome associated with mutations in a second gene different from *BAP1*.

A major strength of this study is that it includes UM sampled from enucleated tumors and FNAs with both somatic and germline *BAP1* mutations. However, it is limited by the small number of tumors with germline mutations. It is important to confirm these findings in a larger cohort of UM.

Conclusions {#Sec11}
===========

This study identified significant differences in the risk of metastasis for individuals whose tumors carry somatic vs. germline *BAP1* mutations. While overall 36 of 59 (61%) metastasizing tumors carried a *BAP1* mutation, only 7% carried germline mutations, compared to 54% with somatic mutations. From the viewpoint of counseling individuals with UM, there are different implications depending on whether the mutation is classified as germline or somatic. The most relevant information for the individuals with UM is the risk of metastasis, as well as an estimate of metastasis-free survival. The presence of germline mutations can provide the individual with information concerning the risk of development of other cancers themselves or in other family members, while information about the presence of somatic mutations is relevant to their individual risk of developing metastases within a shorter time period. Thus it is important to determine whether a tumor carries a *BAP1* mutation, and if positive, to also evaluate a matched blood sample to establish whether the mutation is germline or somatic. In addition, this information can also change the cascade screening and surveillance of the family members.
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Additional file 1:**Table S1.** Comparison of demographic and tumor variables of two cohorts of 142 UM. Description of demographic and tumor variables with pairwise comparisons for 142 divided into two cohorts depending on whether tumors were selected from archived samples for which both tumor and blood samples were available (cohort 1, *N*=90) or tumors for which *BAP1* sequencing was specifically requested (cohort 2, *N*=52). References: 1. OMIM: Tumor predisposition syndrome; TPDS. <https://www.omim.org/entry/614327>. 2. Pilarski R, Rai K, Cebulla C, Abdel-Rahman M.BAP1 Tumor Predisposition Syndrome. 2016 Oct 13 In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® \[Internet\]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK390611/>. **Figure S1.** Kaplan-Meier analysis comparing metastasis-free survival of two cohorts of 142 UM. Kaplan-Meier curves showing metastasis-free survival following treatment for 142 UM stratified by cohort, as described in the legend for Additional file [1](#MOESM1){ref-type="media"}: Table S1. (DOCX 81 kb)
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